Literature DB >> 2257438

Binding of [125I]-endothelin-1 to rat cerebellar homogenates and its interactions with some analogues.

C R Hiley1, C R Jones, J T Pelton, R C Miller.   

Abstract

1. [125I]-endothelin-1, over the concentration range 6 pM-10 nM, bound to a single site in homogenates of rat cerebellum with high affinity (Kd = 2.8 +/- 0.6 x 10(-10) M). The site was present in a concentration of 321 +/- 58 fmol mg-1 protein. 2. The rates of association and dissociation of [125I]-endothelin-1 with the binding site were slow (at 25 degrees C, k+1 = 8.0 +/- 1.3 x 10(5) M-1s-1; k-1 = 2.6 x 10(-4)s-1) and, on addition of a maximally displacing concentration of endothelin-1 (100 nM), 94.0 +/- 8.4% of the [125I]-endothelin-1 was still bound after 14 h. 3. [125I]-endothelin-1 binding was inhibited by a number of naturally occurring or genetically encoded members of the endothelin/sarafotoxin family of peptides. The order of potency was endothelin-3 = sarafotoxin S6b greater than endothelin-2 = endothelin-1 much greater than porcine proendothelin1-39. 4. Binding was also inhibited by analogues in which either one or both of the cystine disulphide bridges had been replaced by substitution with 2 or 4 alanine residues. The tetra-alanyl substituted analogue, [Ala1,3,11,15]endothelin-1, was equipotent with endothelin-1 at inhibiting the binding of [125I]-endothelin-1. [Ala3,11]endothelin-1 and [Ala1,15]endothelin-1, analogues which each contained one of the disulphide bridges from the parent peptide, were respectively 3 and 14 times less potent than the parent peptide. An analogue in which the Glu10 residue had been anisylated was 25 fold less potent than endothelin-1. 5. It is concluded that the structural requirements for binding to the cerebellar sites for [1251]_ endothelin-1 do not require the presence of the disulphide bridges characteristic of the endothelin/ sarafotoxin family. Rather, the binding may be more sensitive to the presence of bulky side chain substituents, at least in the smaller intramolecular loop.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2257438      PMCID: PMC1917680          DOI: 10.1111/j.1476-5381.1990.tb12708.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide.

Authors:  M Yanagisawa; A Inoue; T Ishikawa; Y Kasuya; S Kimura; S Kumagaye; K Nakajima; T X Watanabe; S Sakakibara; K Goto
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

2.  Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain.

Authors:  Y Kloog; I Ambar; M Sokolovsky; E Kochva; Z Wollberg; A Bdolah
Journal:  Science       Date:  1988-10-14       Impact factor: 47.728

3.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

4.  An exact correction to the "Cheng-Prusoff" correction.

Authors:  P J Munson; D Rodbard
Journal:  J Recept Res       Date:  1988

5.  Cloning and sequence analysis of cDNA encoding the precursor of a human endothelium-derived vasoconstrictor peptide, endothelin: identity of human and porcine endothelin.

Authors:  Y Itoh; M Yanagisawa; S Ohkubo; C Kimura; T Kosaka; A Inoue; N Ishida; Y Mitsui; H Onda; M Fujino
Journal:  FEBS Lett       Date:  1988-04-25       Impact factor: 4.124

6.  Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors.

Authors:  J T Pelton; W Kazmierski; K Gulya; H I Yamamura; V J Hruby
Journal:  J Med Chem       Date:  1986-11       Impact factor: 7.446

7.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

8.  Pressor effects of endothelin-1 and some analogs in the perfused superior mesenteric arterial bed of the rat.

Authors:  C R Hiley; S A Douglas; M D Randall
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

9.  Structure-activity relationships of endothelin: importance of the C-terminal moiety.

Authors:  S Kimura; Y Kasuya; T Sawamura; O Shinmi; Y Sugita; M Yanagisawa; K Goto; T Masaki
Journal:  Biochem Biophys Res Commun       Date:  1988-11-15       Impact factor: 3.575

10.  Competitive interaction between endothelin and sarafotoxin: Binding and phosphoinositides hydrolysis in rat atria and brain.

Authors:  I Ambar; Y Kloog; I Schvartz; E Hazum; M Sokolovsky
Journal:  Biochem Biophys Res Commun       Date:  1989-01-16       Impact factor: 3.575

View more
  9 in total

1.  Endothelin regulation of neuropeptide release from nerve endings of the posterior pituitary.

Authors:  M F Ritz; E L Stuenkel; G Dayanithi; R Jones; J J Nordmann
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

2.  Characterization of endothelin receptors on a human neuroblastoma cell line: evidence for the ETA subtype.

Authors:  L C Wilkes; M R Boarder
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

3.  Modulation by endothelium of the responses induced by endothelin-1 and by some of its analogues in rat isolated aorta.

Authors:  S Topouzis; J P Huggins; J T Pelton; R C Miller
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

4.  Endothelium-dependent mesenteric vasorelaxant effects and systemic actions of endothelin (16-21) and other endothelin-related peptides in the rat.

Authors:  S A Douglas; C R Hiley
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

5.  Discrimination between ETA- and ETB-receptor-mediated effects of endothelin-1 and [Ala1,3,11,15]endothelin-1 by BQ-123 in the anaesthetized rat.

Authors:  M Bigaud; J T Pelton
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

6.  A novel ETA-receptor antagonist, FR 139317, inhibits endothelin-induced contractions of guinea-pig pulmonary arteries, but not trachea.

Authors:  L O Cardell; R Uddman; L Edvinsson
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

7.  Characterization of three non-peptide endothelin receptor ligands using human cloned ETA and ETB receptors.

Authors:  K W Buchan; C Alldus; C Christodoulou; K L Clark; C W Dykes; M J Sumner; D M Wallace; D G White; I S Watts
Journal:  Br J Pharmacol       Date:  1994-08       Impact factor: 8.739

8.  Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats.

Authors:  S M Gardiner; P A Kemp; J E March; T Bennett; A P Davenport; L Edvinsson
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

9.  Induction of endothelium-dependent relaxation in the rat aorta by IRL 1620, a novel and selective agonist at the endothelin ETB receptor.

Authors:  H Karaki; S A Sudjarwo; M Hori; M Takai; Y Urade; T Okada
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.